rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Palatin Technologies, Inc.

PTN · Nasdaq

Health CareBiotechnologyNot moving yet

PTN stood above a rising 150-day average in 23 of the last 52 weekly readings, and has been out of that trend for the last 23 weeks. It is 54.6% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 23
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$9,458
Officials’ trades on record
0
Institutions holding
24 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$437.7MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders24+0 on the quarter
New · exited6 · 6
Reported value$7.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Driehaus Capital Management LLCunchanged · filed 14 Aug 2026166,713$1.8M00.0%
Jupiter Topco LLCnew · filed 14 Aug 2026140,000$1.5M+140,000
Logos Global Management LPreduced · filed 14 Aug 2026130,000$1.4M-10,000−7.1%
RA CAPITAL MANAGEMENT, L.P.reduced · filed 14 Aug 202662,124$670K-7,876−11.3%
Balyasny Asset Management L.P.reduced · filed 14 Aug 202641,110$444K-59−0.1%
MORGAN STANLEYunchanged · filed 13 Aug 202627,272$294K00.0%
Opaleye Management Inc.new · filed 14 Aug 202620,500$221K+20,500
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202619,382$209K+880+4.8%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 202618,911$204K-68−0.4%
Miller Financial Services LLCadded · filed 29 Jul 202615,000$162K+2,400+19.0%
31 Mar 2023 – 30 Jun 2026
52035Mar 23Dec 23Sep 24Jun 25Jun 26

Everyone who traded it

Alan W. Dunton Company insiderDirector · last 3 Aug 202611 · 3
Arlene Morris Company insiderDirector · last 3 Aug 20262 · 0
John K. A. Prendergast Company insiderDirector · last 3 Aug 20260 · 0
Carl Spana Company insiderPresident and CEO · last 15 Jul 20268 · 0
Stephen T. Wills Company insiderExecutive VP and CFO/COO · last 15 Jul 20267 · 3
Robert K. Deveer, Jr. Company insiderDirector · last 7 May 20256 · 2
Anthony M. Manning Company insiderDirector · last 15 Jul 20240 · 0
Joseph Stanley Hull Company insiderDirector · last 15 Jul 20245 · 0
Angela Rossetti Company insiderDirector · last 16 Jun 20200 · 0
Zola P. Horovitz Company insiderDirector · last 8 Dec 20151 · 0
Perry B. Molinoff Company insiderDirector · last 25 Jun 20141 · 0
Robert I. Taber Company insiderDirector · last 25 Jun 20141 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2026 · to 30 Jun 2026-116%
Free cash flow marginFY 2026 · to 30 Jun 2026-181%
Return on capital employedFY 2026 · to 30 Jun 2026-128%
Research spendFY 2026 · to 30 Jun 2026165%
Share count trendFY 2026 · to 25 Sep 20260.1%
Cash and equivalentsFY 2026 · to 30 Jun 2026$7.5M
Free cash flowFY 2026 · to 30 Jun 2026−$13.6M

Analyst forecasts

No analyst forecasts yet.